Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. [electronic resource]
Producer: 20050621Description: 3149-55 p. digitalISSN:- 1524-4539
- 3',5'-Cyclic-GMP Phosphodiesterases
- Adrenergic alpha-Antagonists -- pharmacology
- Arteriosclerosis -- complications
- Blood Pressure -- drug effects
- Carbolines -- adverse effects
- Contraindications
- Coronary Disease -- complications
- Cyclic GMP -- metabolism
- Cyclic Nucleotide Phosphodiesterases, Type 5
- Drug Interactions
- Endothelium, Vascular -- drug effects
- Erectile Dysfunction -- drug therapy
- Heart Rate -- drug effects
- Humans
- Hypotension -- chemically induced
- Imidazoles -- adverse effects
- Isosorbide Dinitrate -- analogs & derivatives
- Male
- Molecular Structure
- Myocardial Infarction -- chemically induced
- Nitric Oxide Donors -- pharmacology
- Nitroglycerin -- pharmacology
- Phosphodiesterase Inhibitors -- adverse effects
- Phosphoric Diester Hydrolases -- drug effects
- Piperazines -- adverse effects
- Purines
- Randomized Controlled Trials as Topic
- Sildenafil Citrate
- Sulfones -- adverse effects
- Tadalafil
- Triazines -- adverse effects
- Vardenafil Dihydrochloride
- Vasodilation -- drug effects
- Vasodilator Agents -- adverse effects
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.